JPMorgan lowered the firm’s price target on Syndax to $37 from $38 and keeps an Overweight rating on the shares. The analyst updated models in the SMid cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNDX:
- Syndax management to meet virtually with B. Riley
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Syndax price target lowered to $32 from $34 at Barclays
- Syndax reports Q3 EPS (73c), consensus (78c)
- Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update